Sign up to save your podcasts
Or
Share Issue 2 — Revolutionizing Traditional Medicine with Cannabis-based Medicinal Products
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Issue 2 — Revolutionizing Traditional Medicine with Cannabis-based Medicinal Products
Innovation is the cornerstone of the work we do at Altasciences. When sponsor Tetra Bio-Pharma approached us to conduct a first-in-human test on their product, a cannabis extract being studied for use in breakthrough cancer pain, we collaborated with them on the ideal development plan, including clinical study design and bioanalysis, for the first whole plant cannabis extract following the drug pathway for approval.
Click here to download a readable, PDF version of Issue 2: https://www.altasciences.com/sites/default/files/2022-04/The-Altascientist_issue2_Cannabis_2022.pdf
CHAPTERS:
- 0:08 — Section 1: Introduction to Cannabis-based Medicinal Products
- 1:33 — Section 2: Supporting Clinical Facts and Research
- 6:56 — Section 3: Altasciences' Experience and Innovative Approach to Cannabinoid Studies
- 8:10 — Section 4: Case Study — Safety and Tolerability Study on the World's First Cannabis Extract Being Developed as a Drug for Regulatory Submission
About Altasciences:
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View all episodes
By The Altascientist
5
33 ratings
Innovation is the cornerstone of the work we do at Altasciences. When sponsor Tetra Bio-Pharma approached us to conduct a first-in-human test on their product, a cannabis extract being studied for use in breakthrough cancer pain, we collaborated with them on the ideal development plan, including clinical study design and bioanalysis, for the first whole plant cannabis extract following the drug pathway for approval.
Click here to download a readable, PDF version of Issue 2: https://www.altasciences.com/sites/default/files/2022-04/The-Altascientist_issue2_Cannabis_2022.pdf
CHAPTERS:
- 0:08 — Section 1: Introduction to Cannabis-based Medicinal Products
- 1:33 — Section 2: Supporting Clinical Facts and Research
- 6:56 — Section 3: Altasciences' Experience and Innovative Approach to Cannabinoid Studies
- 8:10 — Section 4: Case Study — Safety and Tolerability Study on the World's First Cannabis Extract Being Developed as a Drug for Regulatory Submission
About Altasciences:
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.